Friendship Zhijie Biological-B (02496.HK) published the M701 malignant ascites Stage II data in "Experimental Hematology and Oncology".

The Zhixun Finance APP reports that Youzhuyou Biology-B (02496.HK) announced that the development and clinical trial results of the investigational bispecific antibody (BsAb) drug M701, targeting both epithelial cell adhesion molecule (EpCAM) and cluster of differentiation 3 (CD3), which was independently developed by the company for the treatment of malignant ascites caused by late-stage epithelial tumors in China, have been published in the internationally renowned medical journal "Experimental Hematology and Oncology." This move signifies that the clinical value of this innovative therapy has received recognition from the international medical community.